IDEXX Cancer Dx testing provides accurate detection of biomarkers specific for lymphoma in canine serum and whole blood. B-cell vs. T-cell phenotype classification will be provided with positive results as available at no additional cost.

IDEXX Cancer Dx testing provides two indications, both for canine lymphoma:

• Aid in diagnosis: IDEXX Cancer Dx testing can be performed on dogs in which lymphoma is suspected, whether that be due to a physical examination abnormality, blood work abnormality or report of illness or change in behaviour at home.
• Screening: In early studies, IDEXX Cancer Dx testing has the potential to detect lymphoma up to 2 months in advance of the onset of clinical signs.¹ This would be most appropriately used in senior dogs (aged 7 years and older) and at-risk breeds aged 4 and older.

At-risk dogs include dogs of all breeds aged 7 or older and dogs of breeds at increased risk for cancer aged 4 or older. These dog breeds have an increased risk for lymphoma: beagle, Bernese mountain dog, boxer, bullmastiff, Doberman pinscher, English bulldog, flat-coated retriever, French bulldog, golden retriever, Labrador retriever, miniature schnauzer, rottweiler, and Scottish terrier. Dog breeds at increased risk for cancer include those above along with these: Boston terrier, Chinese pug, German shepherd, Irish wolfhound, Pembroke Welsh corgi, Rhodesian ridgeback, Scottish deerhound, shar-pei, Siberian husky, and weimaraner.

The specimen requirement for the IDEXX Cancer Dx Test is 2 mL of serum and 1 mL of EDTA whole blood (LTT) when run as a standalone, add-on or in a profile. When included in a profile with chemistry and CBC, the IDEXX Cancer Dx testing is run using a portion of the 2 mL serum and 1 mL EDTA whole blood specimens required for standard biochemistry and haematology testing. A separate pair of tubes are not necessary.

Results will be reported as either ‘consistent with lymphoma’ or ‘not consistent with lymphoma’. If a result is unable to be obtained on the specimen submitted, the customer will be notified appropriately within their results view.